Introduction
Tumour biology can be understood only taking into account both the individual transformed cells and the 'tumour microenvironment' (TME). The TME is a complex array of cells and extracellular matrix (ECM) proteins that tumour cells construct during the course of multistep tumourigenesis [1] and strongly influences the behaviour and malignancy of the transformed cells. Moreover, the TME may change during tumour progression, hence it may differ (structurally and functionally) from the primary tumour to its metastases [2, 3] . The TME greatly varies among cancers of different histogenesis. For example, in leukaemias, it is mainly represented by the bone marrow, with the complex array of stromal and vascular cells which constitute the bone marrow nike, where leukaemia stem cells reside [4] . In carcinomas, a clear distinction is made between the neoplastic cells, named as the 'parenchyma', and the TME, indicated as the 'tumour stroma'. An active and overwhelming tumour stroma (in this case, addressed as 'desmoplastic reaction') characterizes some specific carcinomas, such as breast, prostate or pancreatic cancer (PC) [5] . In particular, the desmoplastic reaction is one of the histopathological and functional hallmarks of PC: histopathological analysis reveals the presence of dense collagen (types I and III) bundles associated with fibroblasts, with loss of basement integrity and invasion of malignant cells into the interstitial matrix with exposure of collagens. The ECM in PC also contains fibronectins, tenascin-C, laminins, mainly secreted by pancreatic stellate cells (PSCs), a cellular phenotype peculiar of PC [6] . The desmoplastic reaction in PC is associated with an abnormal vasculature with numerous circuitous small leaky blood & 2014 The Author(s) Published by the Royal Society. All rights reserved. vessels and capillaries [7] . On the whole, the desmoplastic reaction is one of the major contributors to PC malignancy (see below).
Taking into account the relevance of the tumour stroma, antineoplastic therapeutic strategies must be tuned to target the 'cancer tissue', e.g. not only tumour cells, but also the cellular constituents of the TME [8, 9] . In this context, deciphering the role of ion channel and transporter (ICT) proteins in the crosstalk between the tumour cells and the various constituents of the TME merits particular attention, also from a therapeutic viewpoint.
In this review, we briefly describe the TME as well as ICTs present in the different cells of the TME. For molecular and functional description of ICTs, we refer to other papers [10] . Then, we focus on adhesion receptors of the integrin family, and on their functional interaction with ICT. Because most of these data have been reported elsewhere [11] , in this review, we mainly focus on PC, where the TME drives tumour progression and resistance to therapy.
The tumour microenvironment and its ion channels and transporters profile
The TME comprises both cells (endothelial cells and their precursors, fibroblasts and specialized mesenchymal cells as well as cells of the innate and specific immunity) and the proteins of the ECM. The main ICTs expressed in the cells of the TME have been detailed in [11] and are summarized in table 1. We must remember the prevalent role of Ca 2þ -permeable channels (both voltage-dependent and non-selective channels of the TRP family) in endothelial cells (ECs; reviewed in [18, 19] Inside the TME, both 'cancer-associated fibroblasts' [21] and specialized mesenchymal cells, such as myofibroblasts or the PSCs [22] , are present. Although cancer-associated fibroblasts and specialized mesenchymal cells are not malignant, in that they do not bear cancerogenic mutations, they can exhibit epigenetic changes, which affect their behaviour [23] . Moreover, they are actively secreting ECM proteins, behaving as the main determinant of the desmoplastic reaction. The latter, directly or through the creation of a hypoxic environment, regulates tumour progression and dictates therapy resistance [24] .
Finally, the TME is densely infiltrated by cells of both the innate and adaptive arms of the immune system, whose exact role in controlling tumour progression is still debated [25, 26] . Neutrophil ion channels (mainly TRPs, K Ca and Cl -channels; reviewed in [27] ) are exploited to accomplish the antimicrobial activity which characterizes these cells of innate immunity. Macrophages express K IR channels, which are involved in cell adhesion, and in turn affect the Ca 2þ -dependent macrophage activation [28] . Macrophages also express P2X7 receptors, which mediate the release of lysosomal cathepsin [29] . This fact could contribute to ECM remodelling, with a strong impact on malignant progression. The complex array of ion channels which contribute to T lymphocyte activation has been thoroughly described [15, 16] : a coordinated influx of Ca 2þ is indeed essential to trigger T lymphocyte activation, and an unique contingent of ion channels (including Kv1.3 and K Ca 3.1 K þ channels) orchestrate the duration and intensity of the Ca 2þ signals. Moreover, the balance of these channel types constitutes a specific functional marker of activated lymphocytes, thus providing a possible novel therapeutic target [11] . The ECM of the TME comprises proper matrix proteins, a multitude of growth factors and cytokines that, more or less directly, affect malignant cells [30] . Type I collagen, fibronectin and thrombospondins are the ECM proteins which [11] bone marrow mesenchymal cells K ATP [13] bone marrow -umbilical cord vein mesenchymal cells characterize the TME, with collagen I being the main determinant of the desmoplastic reaction. ECM proteins can affect tumour progression by controlling cell motility as well as by dictating tumour cell differentiation programmes [30] . The ECM of the TME is produced by both tumour and mesenchymal cells, which also modulate their ECM by secreting proteases [31] . TME remodelling can lead to the release of molecules sequestered in the ECM, such as the vascular endothelial growth factors [32] , and many cleavage products of ECM proteins [2] , which further control tumour angiogenesis and metastasis formation.
The crosstalk between the ECM and tumour cells, as well as of the cellular components of the TME, is mainly mediated through the intervention of adhesion receptors of the integrin family.
Cell adhesion molecules: the integrin family (a) Integrin structure and function
Integrin receptors are transmembrane proteins formed by noncovalent association of a-and b-subunits. To date, 18 a-and eight b-subunits are known in mammals. All subunits are type I transmembrane glycoproteins with a short cytoplasmic tail (20-70 amino acids), a membrane-spanning helix and a large multidomain extracellular portion [33] . The b4-subunit is an exception because its cytoplasmic domain contains around 1000 amino acids [34] . Integrin subunits can combine to form at least 24 functional heterodimers, each of which binds a specific array of ECM proteins, or cell adhesion molecules (CAMs), that act as 'counterreceptors'.
Integrins are more than CAMs: they can transmit bidirectional signals across the plasma membrane. On the cell surface, integrins are normally in the low affinity state, and they can be activated through an 'inside-out' signalling pathway. During this process, two cellular activators, talin and kindlin, play an essential role, and the binding of talin to the b integrin cytoplasmic tail is proposed to be the final step in integrin activation [35] . Conversely, the binding of the integrin extracellular ligands transmits signals inward, a process called 'outside-in' signalling. Outside-in signalling of integrin exerts significant influences on cell mobility, proliferation, differentiation, etc. [36] . Because the list of papers describing the many facets of integrin-mediated signalling pathways is immense, we refer to those [33, 37, 38] , and only limit to summarize that integrins seem to be linked to almost all of the known signalling pathways, including induction of cytosolic kinases, stimulation of the phosphoinositide metabolism, activation of Ras/MAPK and protein kinase C (PKC) pathways and regulation of small GTPases. Moreover, integrin signalling often overlaps with that triggered by growth factor or cytokine receptors [38] . The overlap and proper integration of differently arising signals, makes physiological sense, because cells must integrate multiple stimuli from the ECM, growth factors, hormones and mechanical stress, to organize appropriate responses. The same integration occurs and determines the fate of even more in tumour cells inside the cancer tissue.
(b) Integrin relationships with ion channels
The relationships between integrins and ion channels in the cell-to-cell and cell-to-matrix interactions have been long described [39] . The earliest indications came from studies on neuronal and leukaemic cells, in which many cellular processes elicited by the engagement of adhesive proteins, such as differentiation, migration and neurite extension, turned out to depend on ion channel activation [40] [41] [42] [43] . When associated with integrins, ion channel function becomes bidirectional itself: it is regulated by extracellular signals (through integrins) and in turn controls integrin activation and/or expression [39] . Interestingly, the same kind of complex bidirectional signalling has been observed for some ion transporters, in particular those mediating proton fluxes [44] [45] [46] , which are so relevant in the establishment of a reversed H þ gradient which characterizes neoplastic malignancy [47] . The bidirectional crosstalk between integrins and ion channels occurs through different mechanisms: it may rely on cytoplasmic messengers, such as Ca 2þ or protein kinases, commuting between the two proteins (reviewed in [39] ). For example, T lymphocyte activation in which b1 integrins are involved is underlied by a coordinated influx of Ca 2þ , which is controlled by and, conversely, regulates K þ channels [16] . The transmission of mechanical forces at focal adhesion sites is triggered by integrins and mediated by calcium [48] , but also involves the activation of signalling molecules, such as FAK and c-Src [49] . Another aspect of integrin/ion channel interaction is the fact that integrins and ion channels can interact directly at the plasma membrane level. In other words, the two proteins co-assemble on the plasma membrane and give rise to supramolecular complexes, which constitute platforms for triggering and orchestrating downstream intracellular signals. The first evidence was obtained in immune cells by Levite et al. [50] , who found that the b1 integrin subunit associated with Kv1.3 channels in T lymphocytes. Shortly afterwards, a physical link between Kv1.3 channels and b1 integrins was described in melanoma cells [ Another mechanism involving the interaction between integrins and ion channels contributes to determine integrin recycling [57] . In particular, CLIC3 chloride channels colocalize with active a5b1 integrins in late endosomes/lysosomes, allowing the integrin to be retrogradely transported and recycled to the plasma membrane at the cell rear. This mechanism also involves Rab25 and has a clear impact on cancer behaviour. In fact, in PC, active integrins and CLIC3 are necessary for cancer cell invasion [57] .
(c) Integrins and ion channels: role in cell migration
A most interesting aspect regards the comprehension of several mechanisms by which integrins and different channel types interact in controlling cell migration. Besides being a fundamental component of embryogenesis and tissue remodelling in the adult, these processes are relevant in tumour cell invasiveness and metastatic spread. As typical mediators of cell interaction with the environment, it is not surprising that integrins play major roles in eukaryotic cell migration. ] and will not be discussed in detail here. We limit our discussion to the fact that K þ channels can form complexes, and thereby modulate several proteins involved in cell movement, such as FAK [60, 61] , cortactin [62, 63] and integrins themselves. Interesting speculations can derive from studies on a9b1 integrins, which can regulate cell movement by activating inward rectifier K þ channels (IRK) [64] . IRK channels, along with the integrin, are physically linked to spermidine/xspermine N1-acetyltransferase, the key enzyme in the pathway that acetylates spermine and spermidine to putrescine, thus controlling the intracellular concentration of polyamines. Polyamines are critical regulators of neoplastic growth and also the main intracellular messengers controlling IRK activity. A functional network may hence be figured out, where an adequate intracellular concentration of polyamines converges to trigger a proper a9b1-dependent cell movement, through the modulation of IRK channels [65] .
(d) Integrins and ion channels in the cells of the tumour microenvironment
Integrins and ion channels also interact at the level of the TME. One example involves cells of the innate immune system: neutrophils release Cl -to accomplish their antimicrobial activity; Cl -release occurs through the activation of Cl -channels which is, at least in part, dependent on b 2 integrin-mediated adherence to fibronectin [66] . Macrophages express K IR channels, whose activity is modulated by VLA4 (a4b1) integrin receptors and hence by cell adhesion, which in turn affects the Ca 2þ -dependent macrophage activation [28] . Another example is represented by ECs and their Cl channels of the CLCA protein family. In ECs, CLCA2 behaves as a vascular addressin for metastatic, blood-borne, cancer cells, facilitating vascular arrest of cancer cells via adhesion to b4 integrins, and hence promoting metastatic spread. In addition, the b4-integrin-CLCA complex stimulates Src-dependent cell signalling through FAK and extracellular signal-regulated kinase (ERK), leading to increased proliferation of metastatic foci [67] . A list of ion channels physically or functionally linked to integrins in the cells of TME is reported in table 2.
The role of the tumour microenvironment
in the progression of pancreatic cancer PC, mainly represented by the histological form of pancreatic ductal adenocarcinoma, is one of the most lethal gastrointestinal malignancies, representing the second leading cause of death among them. The overall 5-year survival rate is less than 6%, in the most recent American Database (http:// seer.cancer.gov/csr/1975_2006), and a median survival of 18 months from diagnosis for those operated-on patients with no evidence of residual disease. Similar disappointing figures are available from European surveys [69] . The malignant nature of PC is mainly due to its aggressive growth and rapid development of distant metastases, thus making treatment extremely difficult. Additionally, PC is locally invasive, surrounded by a dense desmoplastic reaction (see §1) which can involve adjacent vital structures, limiting the chance for complete resection. Indeed, less than 20% of patients are candidates for surgical resection at the time of diagnosis, while almost one half have metastatic disease. Moreover, of the few patients who undergo surgery with radical intent (R0), most will develop a recurrence within 15 months. Although surgery remains the cornerstone of cure, the addition of adjuvant treatments is required [70] . Chemotherapy (in Europe) or radiochemotherapy (in North America) has been used, either as adjuvant to surgery or as definitive treatment for unresectable disease, with conflicting results [71, 72] . Failure of traditional therapeutic approaches for this devastating disease had led to many efforts towards the study of molecular biology and targeted therapies, in order to create a multimodal therapeutic strategy [73] . Among target therapy drugs, only erlotinib that targets the EGF-R, has been shown to improve survival when used in combination with gemcitabine, compared with gemcitabine alone. Nevertheless, the clinical response rate remains modest, mainly owing to the intrinsic chemoresistance of PC cells [74] . Investigating mechanisms mediating chemoresistance is therefore of clinical interest in drug development of new agents. As stated in §1 one of the major contributors to PC malignancy and therapy resistance is represented by the desmoplastic reaction. Further understanding of how the TME facilitates PC cell malignancy will identify unique targets that may finally improve the treatment of patients with PC [6] . Some insights are briefly reported below. [16, 50] rstb.royalsocietypublishing.org Phil. Trans. R. Soc. B 369: 20130101 endocrine pathway. These interactions in normal development require specific proteins within the ECM, notably laminin. Crosstalk between mesenchymal and epithelial compartments occurs through soluble messengers acting on a paracrine (or autocrine) manner, cell-surface receptor activation through direct cell-to-cell contact, and specific ECM proteins secreted by mesenchymal cells [75, 76] . Perturbations of the normal mesenchymal-epithelial interactions can lead to unregulated cell growth, as occurs in cancer. PSCs are the predominant mesenchymal cells within the PC stroma and the main determinant of the desmoplastic reaction [77] . PSCs originate from bone-marrow-derived mesenchymal stem cells, and are similar to myofibroblasts found in other tumour stroma (breast, prostate cancer). PSCs have the ability to transdifferentiate from a 'quiescent', retinoid/lipid storing phenotype in the normal pancreas to an 'activated', a-smooth muscle actin producing myofibroblastic phenotype. Activators of PSCs in vivo include cytokines (IL1, IL6, IL8 and TNF-a) growth factors (PDGF and TGF-b) and reactive oxygen species released by damaged inflammatory cells recruited in response to injury to the pancreas. Activated PSCs, in turn, can produce autocrine factors, such as PDGF, TGF-b, cytokines and proinflammatory molecules which may potentiate an activated phenotype [77] [78] [79] . PSCs, besides being implicated in the genesis of chronic pancreatitis, are critical for the development of the desmoplastic reaction in PC, being the main source of ECM proteins [78] . Moreover, because PSCs are activated by PC cells in vitro, a synergistic relationship between the two types of cells occurs, that favours the development and progression of PC.
(b) Integrins in pancreatic cancer
In PC, it is well established that ECM proteins, such as collagen, fibronectin and tenascin-C, interact with cell-surface integrins to provide intracellular signals to both PSCs and PC cells [80] . For example, in PSCs, b1 integrins are important not only to modulate cell adhesion to the basement membrane, but also to determine the proper formation and differentiation of acini during normal development [81] . PC cells express at least two major classes of integrins: b1-containing integrins (mainly a2b1 and a5b1), which mediate cell adhesion to fibronectin, laminin and collagen (type I and IV), and avb5, which is mainly involved in PC cell adhesion to vitronectin [82, 83] . Integrin engagement has been reported to determine the malignant phenotype of PC cells by regulating cell proliferation [82] , invasion [84] as well as by cytokine secretion [85] . For example, tenascin-C can affect PC cell growth and migration through the activation of b1 integrin intracellular signalling pathways [86] . Some recent evidence indicates that intergrin involvement in PC cell invasion can also occur through a complex interaction with EGF receptor (EGF-R) and the modulation of Src-centred intracellular signalling pathways [84] .
On the whole, integrins, mainly those containing the b1 subunit, being expressed both in PC cells and in PSCs, and regulating the production of ECM proteins by the latter, are pivotal in regulating tumour-stroma interaction in PC. b1 integrins can hence drive different aspects of tumour cell behaviour, including chemo-and radio-resistance (see below).
(c) Ion channels and transporters in pancreatic cancer
In the past few years, different ICT proteins have been characterized in PC cells: TRP cationic channels of the 'melastatin-related' type (TRPM) have been reported to be overexpressed in PC cells.
In particular, both TRPM8 [87] and TRPM7 [88] are overexpressed in pancreatic ductal adenocarcinoma cells, where they regulate either cell proliferation or migration. TRPM7 activation triggers a Mg 2þ -sensitive 'suppressor of cytokine signalling 3a'
(Socs3a) pathway, which regulates exocrine pancreatic epithelial cell proliferation, both in development and cancer [89] . Moreover, Dong et al. [90] [91] . Because hERG1 physically and functionally interacts with b1 integrins in different tumour cells (see above) including PC [91] , it is tempting to speculate that it could drive PC malignancy through the modulation of integrin-mediated signalling. Finally, the sodium hydrogen exchanger 1 (HNE1) is expressed in PC cells [92, 93] and is activated by growth factors such as neurotensin (NT). The NT/ HNE1 pathway may be implicated in the early progression of PC by localized acidification and induction of an aerobic glycolytic phenotype with higher metastatic potential.
A model illustrating tumour-stroma interaction in PC, as well as the involvement of integrins, is reported in figure 1 . Those ICTs which interact with integrins to modulate the crosstalk between PC cells and the TME are also illustrated.
(d) The tumour microenvironment drives therapy resistance in pancreatic cancer
The altered crosstalk between stromal ECM proteins and integrins expressed on both tumour and TME cells is also implicated in mechanisms of acquired resistance to chemo-and radiotherapy in PC. An in vitro study using different PC cell lines cultured in the presence of collagen, fibronectin or laminin, showed different induction of chemosensitivity, depending on the type of substrate [94] . Indeed, inhibiting ECM-integrin function in combination with chemotherapy may be a potential therapeutic intervention that could specifically target the desmoplastic reaction. One example could be the monoclonal antibody targeting a5b1 or avb3 integrin (Vitaxin). Moreover, PSCs are known to promote radioprotection of PC cells: this effect is dependent on a signalling pathway triggered by b1 integrin and converging on FAK [95] . Treatment failure in PC may be due, at least in part, to our limited understanding of how the fibrotic tissue and the stromal cells present within this tumour can facilitate the rapid progression of this cancer type. Therefore, a better understanding of the mechanisms which regulate PC cell interactions with the TME, with particular attention to the crosstalk between integrins and ICTs, could open a new perspective to effectively treat PC. 
